STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy

Y Wang, H Qi, T Wang, W Zhang, X Shi… - Journal of …, 2024 - Taylor & Francis
A total of 162 non-small cell lung cancer (NSCLC) patients were divided into discovery (N=
68) and validation (N= 94) groups. Nine Janus kinase/Signal transducer and activator of …
相关文章

STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy.

Y Wang, H Qi, T Wang, W Zhang, X Shi… - Journal of …, 2023 - europepmc.org
A total of 162 non-small cell lung cancer (NSCLC) patients were divided into discovery (N=
68) and validation (N= 94) groups. Nine Janus kinase/Signal transducer and activator of …

STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy

Y Wang, H Qi, T Wang, W Zhang… - Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
A total of 162 non-small cell lung cancer (NSCLC) patients were divided into discovery (N=
68) and validation (N= 94) groups. Nine Janus kinase/Signal transducer and activator of …